Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

/p>

3 months to September 9 months to September 30, 30, 2011 2010 2011 2010 $M $M $M $M Net cash provided by operating activities 178.7 142.0 664.2 612.0 Capital expenditure (1) (40.9) (53.5) (135.9) (139.7) Non GAAP free cash flow 137.8 88.5 528.3 472.3

(1) Capital expenditure for the nine months ended September 30, 2010 excludes capital expenditure relating to the acquisition of Lexington Technology Park.

Non GAAP net debt comprises:

September 30, December 31, 2011 2010 $M $M Cash and cash equivalents 276.4 550.6 Restricted cash 21.0 26.8 Convertible bonds (1,100.0) (1,100.0) Building finance obligation (8.3) (8.4) Non GAAP net debt (810.9) (531.0)

NOTES TO EDITORS

THE "SAFEHARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of Shire's Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicines products, as well as the ability to secure new products for commercialization and/or development; government regulation of Shire's products; Shire's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on Shire's products; Shire's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; Shire's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... & Rockville, MD (PRWEB) July 29, 2014 ... Inc. (ITI), a vaccine pioneer in the biotechnology ... services firm Newport Coast Securities, Inc. to explore ... is commercializing LAMP-vax technology, a breakthrough vaccine platform ... and immunotherapy market. The company exclusively licensed the ...
(Date:7/29/2014)... 29, 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ... increased its investment in Green Chemistry and donated more ... last year, the Company announced Monday in its new ... the World? The report comes in ... being a responsible corporate citizen, including recognition for the ...
(Date:7/29/2014)...  United Therapeutics Corporation (NASDAQ: ... for the second quarter ended June 30, 2014. ... our medicines are reaching increasing numbers of ... said Martine Rothblatt, Ph.D., United Therapeutics, Chairman ... this quarter of our extended-release tablet called ...
(Date:7/29/2014)... 29, 2014 Eppendorf Centrifuge 5427 ... selection. Eppendorf 5427 R is geared towards high-end applications ... it is targeted towards work requiring high sample throughput. ... as it compliments their extensive 16, 48, and 64 ... microcentrifuge tubes, PCR tubes, PCR strip tubes, and more. ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2
... energy company, BioPower Systems (BPS), today announced that the ... O,Brien MP, has awarded the company conditional funding support ... Program. The funding will be applied towards ... bioWAVE ocean wave energy system at a grid-connected site ...
... Medical Center researchers could still be close to giving heart ... The "LateTIME" trial was a study of adult ... to have the ability to improve heart function after an ... the attack. Results were released this week ...
... Palatin Technologies, Inc. (NYSE Amex: ... peptide therapeutics for the treatment of diseases with ... announced that Dr. Carl Spana, President and Chief ... Area Partnerships conference on Thursday, December 1, 2011.  ...
Cached Biology Technology:BioPower Systems Awarded $5 Million from Victorian Government 2BioPower Systems Awarded $5 Million from Victorian Government 3Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise 2Palatin Technologies to Present at Windhover's Therapeutic Area Partnerships Conference 2
(Date:7/29/2014)... in locomotion. Swimming microorganisms, such as bacteria and spermatozoa, ... the viscous forces exerted by the surrounding fluid. ... scientists have found that the direction of propulsion made ... by a viscoelastic fluid. These findings have been published ... the Alternative Energies and Atomic Energy Commission (CEA), in ...
(Date:7/29/2014)... wildfires that have been plaguing the Northern Territories in ... Great Lakes in the U.S. continue on. NASA,s ... Resolution Imaging Spectroradiometer, MODIS, instrument on July 26, 2014. ... outlined in red. Copious amount of smoke are drifting ... havoc for residents of Yellowknife. Fire has caused ...
(Date:7/29/2014)... the University of Kent has shown for the first ... a breakthrough that could have a major impact on ... of Biosciences uncovered the mechanism whereby the physical properties ... actin filaments are ,fine-tuned, to undertake different functions. ... completely stable, providing a framework for the cell, others ...
Breaking Biology News(10 mins):Optimum inertial self-propulsion design for snowman-like nanorobot 2
... GOCE satellite from the Plesetsk cosmodrome in northern Russia had ... due to an anomaly identified in one of the units ... stage (Breeze KM ). The correction of the problem ... perform this operation, it will be necessary to de-mate the ...
... physician-geneticist and leader of the Human Genome Project, has ... the Inamori International Center for Ethics and Excellence at ... and Kyoto Prizes for science, technology, philosophy and the ... ethical leaders. It is presented annually to an individual ...
... de los Alimentos (Institute of Nutrition and Food Technology) ... doing research into the positive effects of Mediterranean diet,s ... is a new research line about pancreatic cancer cells. ... points out that in the study ,Influence of the ...
Cached Biology News:Leader of Human Genome Project honored with the Inamori Ethics Prize 2New studies on the Mediterranean diet confirm its effectiveness for chronic disease prevention 2
... The Label IT siRNA Tracker Intracellular Localization ... directly label and deliver siRNA, of your ... for in vitro tracking experiments. Subcellular localization ... can be monitored following introduction of the ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
... and reproducible immunoprecipitation (IP) by using a 96 ... than regular IPs, which are problematic with regards ... the agarose bed. The binding of the antibody/antigen ... elution of the immune complex can occur with ...
... The Yeast Oligo Microarray Kit (V2), ... to simultaneously characterize expression of many ... gene activity during important biological processes. ... representing 6,256 known ORFs from the ...
Biology Products: